Theme 1 (Population Health) will determine how common AMD/PCV is and the factors leading to increased risk of AMD/PCV in Asians to help plan future preventative interventions.
Theme 2 (Pathophysiology) will examine the underlying pathophysiological changes at the cellular/molecular/genetic level in AMD through cell-based and animal experiments.
Theme 3 (Novel Imaging Biomarkers) will exploit a multitude of novel imaging technologies in collaboration with industry partners to find ways in which imaging can help guide treatment to achieve better outcomes.
Theme 4 (Therapy) will test and develop new therapeutic strategies through multi-centre clinical trials.
Theme 5 (Quality Of Life) will determine how AMD/PCV affects the quality of life among Asian patients, the cost of healthcare and also investigate the effect of new behavioral therapy to improve coping strategies among patients.
TAAP: targeted at addressing Unmet Needs
FOCUS: Broad-based, bench-to-bedside-to-population, addressing clinical gaps
TEAM: International, multi-disciplinary team of clinicians, clinician scientists and researchers across all healthcare institutions in Singapore, with leading Asian collaborators with a strong track record in Asian AMD research
Characterise disease burden and risk factors
Clinical and Healthcare Significance
Research Track Record and Expertise
Lead & Theme Principal Investigator
Prof Cheng Ching-Yu, SERI/SNEC/Duke-NUS
Prof Wong Tien Yin, SNEC/SERI/Duke-NUS
Assoc Prof Wang Xiaomeng, IMCB/NTU
Prof Leopold Schmetterer, SERI/NTU
Assoc Prof Caroline Chee, NUHS/NUS
Prof Gemmy Cheung, SNEC/SERI (Corresponding and Lead Principal Investigator)
Assoc Prof Colin Tan, TTSH/NTU
TAAP Governance Structure
Patient and Public Engagement
Epidemiological and risk factor data (Theme 1)
Novel candidate targets (Theme 2)
Development of novel amyloid imaging technology (Theme 3)
Development of novel imaging biomarkers (Theme 3)
Long term follow up of clinical trials (Theme 4, collaborations with pharmaceutical companies and imaging companies)
Subscribe to our mailing list to get the updates to your email inbox...